Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308997 | 0.89 | CA1 (0.38) | CA1CA2CA9HDAC1HDAC6 | |
| SCHEMBL25898246 | 0.85 | CA1 (0.40) | CA1CA2CA9HDAC1HDAC6 | |
| SCHEMBL25898808 | 0.81 | CA1 (0.38) | CA1CA2CA9HDAC1HDAC6 | |
| SCHEMBL31152821 | 0.80 | CA12 (0.40) | CA1CA2CA9CA12L3MBTL1 | |
| SCHEMBL31152820 | 0.80 | CA12 (0.40) | CA1CA2CA9CA12L3MBTL1 | |
| SCHEMBL25309499 | 0.79 | EPHX2 (0.40) | — | |
| SCHEMBL26683595 | 0.78 | SMN1; SMN2 (0.36) | MAPTNPSR1KDM4ECYP1A2 | |
| SCHEMBL25261703 | 0.78 | SMN1; SMN2 (0.33) | MAPTNPSR1TDP1KDM4ECYP1A2 | |
| SCHEMBL30737099 | 0.77 | NPSR1 (0.44) | CA1CA2CA9CA12L3MBTL1 | |
| SCHEMBL19489299 | 0.77 | EPHX2 (0.50) | CA1CA2CA9HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | CA1 3988/4885CA2 3981/4885CA9 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.